Human medicines European public assessment report (EPAR): Axumin, fluciclovine (18F), Date of authorisation: 21/05/2017, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Tepezza, teprotumumab, Date of authorisation: 19/06/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Flucelvax, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 15/11/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad, influenza vaccine (surface antigen, inactivated, adjuvanted), Date of authorisation: 15/11/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Fluenz, influenza vaccine (live attenuated, nasal), Date of authorisation: 03/06/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Waylivra, volanesorsen, Date of authorisation: 03/05/2019, Revision: 7, Status: Authorised

Joint Heads of Medicines Agencies (HMA)/European Medicines Agency (EMA) multistakeholder workshop on Patient Registries for Alzheimer's disease, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 15 December 2025, 09:00 (CET) to 15 December 2025, 17:30 (CET)

Human medicines European public assessment report (EPAR): Vfend, voriconazole, Date of authorisation: 19/03/2002, Revision: 57, Status: Authorised

PSUSA/00009326/202411